JPWO2022136642A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2022136642A5 JPWO2022136642A5 JP2023538891A JP2023538891A JPWO2022136642A5 JP WO2022136642 A5 JPWO2022136642 A5 JP WO2022136642A5 JP 2023538891 A JP2023538891 A JP 2023538891A JP 2023538891 A JP2023538891 A JP 2023538891A JP WO2022136642 A5 JPWO2022136642 A5 JP WO2022136642A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- sequence
- antibody
- pharma
- ester
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP20216800.1 | 2020-12-23 | ||
| EP20216800 | 2020-12-23 | ||
| PCT/EP2021/087495 WO2022136642A1 (en) | 2020-12-23 | 2021-12-23 | Tumor-specific claudin 18.2 antibody-drug conjugates |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2024500242A JP2024500242A (ja) | 2024-01-05 |
| JPWO2022136642A5 true JPWO2022136642A5 (https=) | 2025-01-17 |
| JP2024500242A5 JP2024500242A5 (https=) | 2025-01-17 |
Family
ID=73856974
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023538891A Pending JP2024500242A (ja) | 2020-12-23 | 2021-12-23 | 腫瘍特異的クローディン１８．２抗体と薬物との複合体 |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20240100180A1 (https=) |
| EP (1) | EP4267194A1 (https=) |
| JP (1) | JP2024500242A (https=) |
| KR (1) | KR20230124037A (https=) |
| CN (1) | CN116635085A (https=) |
| AU (1) | AU2021405049A1 (https=) |
| CA (1) | CA3199830A1 (https=) |
| CL (1) | CL2023001800A1 (https=) |
| IL (1) | IL302894A (https=) |
| MX (1) | MX2023007644A (https=) |
| PE (1) | PE20231561A1 (https=) |
| TW (1) | TW202241519A (https=) |
| WO (1) | WO2022136642A1 (https=) |
| ZA (1) | ZA202305221B (https=) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4069738A1 (en) * | 2019-12-06 | 2022-10-12 | SOTIO Biotech a.s. | Humanized cldn18.2 antibodies |
| US20240350589A1 (en) | 2021-08-13 | 2024-10-24 | Cytune Pharma | Il-2/il-15rbetagamma agonist combination with antibody-drug conjugates for treating cancer |
| US20260071003A1 (en) | 2022-09-01 | 2026-03-12 | University Of Georgia Research Foundation, Inc. | Compositions and methods for directing apolipoprotein l1 to induce mammalian cell death |
| CN115368435B (zh) * | 2022-09-06 | 2025-04-18 | 联宁（苏州）生物制药有限公司 | 一种抗体偶联药物连接子set0568的合成方法 |
| WO2024137619A1 (en) | 2022-12-20 | 2024-06-27 | Bolt Biotherapeutics, Inc. | Anti-claudin, bis-benzimid azole sting agonist immunoconjugates, and uses thereof |
| WO2024173387A1 (en) | 2023-02-14 | 2024-08-22 | Bolt Biotherapeutics, Inc. | Aza-benzazepine immunoconjugates, and uses thereof |
| CN119139489A (zh) * | 2023-06-16 | 2024-12-17 | 信达生物制药(苏州)有限公司 | 靶向Claudin18.2的抗体-药物偶联物用于治疗实体瘤的方法 |
| IL326136A (en) | 2023-08-07 | 2026-03-01 | Revolution Medicines Inc | RMC-6291 for use in the treatment of a disease or disorder associated with the RAS protein |
| WO2025078686A1 (en) | 2023-10-12 | 2025-04-17 | Sotio Biotech A.S. | Combination therapy involving antibody-drug conjugates against claudin18.2 and pd1/pd-l axis inhibitors for treatment of cancer |
| US20250154171A1 (en) | 2023-10-12 | 2025-05-15 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025171296A1 (en) | 2024-02-09 | 2025-08-14 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025240847A1 (en) | 2024-05-17 | 2025-11-20 | Revolution Medicines, Inc. | Ras inhibitors |
| US20250375445A1 (en) | 2024-06-07 | 2025-12-11 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2025265060A1 (en) | 2024-06-21 | 2025-12-26 | Revolution Medicines, Inc. | Therapeutic compositions and methods for managing treatment-related effects |
| WO2026006747A1 (en) | 2024-06-28 | 2026-01-02 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026015825A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Use of ras inhibitor for treating pancreatic cancer |
| WO2026015796A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015790A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015801A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026050213A1 (en) | 2024-08-27 | 2026-03-05 | Usbolt Biotherapeutics, Inc. | Tlr agonist immunoconjugates and uses thereof |
| WO2026050446A1 (en) | 2024-08-29 | 2026-03-05 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026072904A2 (en) | 2024-09-26 | 2026-04-02 | Revolution Medicines, Inc. | Compositions and methods for treating lung cancer |
Family Cites Families (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2000015659A2 (en) | 1998-09-16 | 2000-03-23 | Zymogenetics, Inc. | Stomach polypeptide zsig28 |
| DE10254601A1 (de) | 2002-11-22 | 2004-06-03 | Ganymed Pharmaceuticals Ag | Differentiell in Tumoren exprimierte Genprodukte und deren Verwendung |
| DE102004024617A1 (de) | 2004-05-18 | 2005-12-29 | Ganymed Pharmaceuticals Ag | Differentiell in Tumoren exprimierte Genprodukte und deren Verwendung |
| EP1790664A1 (en) | 2005-11-24 | 2007-05-30 | Ganymed Pharmaceuticals AG | Monoclonal antibodies against claudin-18 for treatment of cancer |
| EP1997832A1 (en) | 2007-05-29 | 2008-12-03 | Ganymed Pharmaceuticals AG | Monoclonal antibodies against Claudin-18 for treatment of cancer |
| CN102159248B (zh) * | 2008-07-15 | 2013-09-11 | 健泰科生物技术公司 | 蒽环类衍生物缀合物、它们的制备方法以及它们作为抗肿瘤化合物的用途 |
| WO2013167153A1 (en) * | 2012-05-09 | 2013-11-14 | Ganymed Pharmaceuticals Ag | Antibodies useful in cancer diagnosis |
| WO2013174404A1 (en) | 2012-05-23 | 2013-11-28 | Ganymed Pharmaceuticals Ag | Combination therapy involving antibodies against claudin 18.2 for treatment of cancer |
| EP2869851A1 (en) * | 2012-07-09 | 2015-05-13 | Genentech, Inc. | Immunoconjugates comprising anti-cd22 antibodies |
| WO2014075788A1 (en) | 2012-11-13 | 2014-05-22 | Biontech Ag | Agents for treatment of claudin expressing cancer diseases |
| WO2014127785A1 (en) | 2013-02-20 | 2014-08-28 | Ganymed Pharmaceuticals Ag | Combination therapy involving antibodies against claudin 18.2 for treatment of cancer |
| TWI725931B (zh) | 2013-06-24 | 2021-05-01 | 美商建南德克公司 | 抗ｆｃｒｈ５抗體 |
| SG11201705041WA (en) * | 2014-12-23 | 2017-07-28 | Nbe-Therapeutics Ag | Binding protein drug conjugates comprising anthracycline derivatives |
| WO2016165762A1 (en) | 2015-04-15 | 2016-10-20 | Ganymed Pharmaceuticals Ag | Drug conjugates comprising antibodies against claudin 18.2 |
| AU2017294276B2 (en) | 2016-07-08 | 2024-08-01 | Crage Medical Co., Limited | Antibody for anti-claudin 18A2 and use thereof |
| EP3634401A1 (en) * | 2017-06-07 | 2020-04-15 | Silverback Therapeutics, Inc. | Antibody construct conjugates |
| JP7398380B2 (ja) | 2018-03-08 | 2023-12-14 | フェインズ セラピューティクス，インコーポレーテッド | 抗クローディン１８．２抗体及びその使用 |
| WO2019175617A1 (en) | 2018-03-10 | 2019-09-19 | Pratik Sharma | Data redundancy and elimination module |
| US11485782B2 (en) * | 2018-03-14 | 2022-11-01 | Beijing Xuanyi Pharmasciences Co., Ltd. | Anti-claudin 18.2 antibodies |
| SG11202007074PA (en) | 2018-05-18 | 2020-08-28 | Lanova Medicines Ltd Company | Anti-claudin 18.2 antibodies and uses thereof |
| CN111867630B (zh) | 2018-06-17 | 2023-10-13 | 上海健信生物医药科技有限公司 | 靶向cldn18.2的抗体、双特异性抗体、adc和car及其应用 |
| US11505618B2 (en) | 2018-07-18 | 2022-11-22 | Askgene Pharma Inc. | Antibodies and methods for making and using the same |
| CN112770723B (zh) | 2018-07-25 | 2024-08-02 | 阿克罗斯生物科学公司 | Cldn 18.2特异性单克隆抗体及其使用方法 |
| JOP20210022A1 (ar) | 2018-08-03 | 2021-01-28 | Amgen Inc | بنيات جسم مضاد لـ cldn18.2وcd3 |
| WO2020038404A1 (zh) | 2018-08-22 | 2020-02-27 | 瑞阳(苏州)生物科技有限公司 | 抗人claudin 18.2单克隆抗体及其应用 |
| EP3878863A4 (en) | 2018-08-27 | 2022-06-22 | Nanjing Sanhome Pharmaceutical Co., Ltd. | ANTI-CLAUDIN18.2 ANTIBODIES AND ITS USE |
| US20220033491A1 (en) | 2018-09-30 | 2022-02-03 | Cafa Therapeutics Limited | Combination therapy of cldn18 antibody and chemotherapy drugs |
| BR112021007690A2 (pt) | 2018-10-22 | 2021-08-10 | Shanghai GenBase Biotechnology Co., Ltd. | anticorpo anti-cldn18.2 e uso do mesmo |
| CN113227135B (zh) | 2018-12-28 | 2025-03-21 | 斯帕克斯治疗公司 | 用于治疗癌症和其他疾病的对紧密连接蛋白18.2具有特异性的结合分子、其组合物和方法 |
| US12297265B2 (en) | 2018-12-28 | 2025-05-13 | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | Antibody and use thereof |
| CN113227146B (zh) | 2018-12-28 | 2024-03-01 | 南京金斯瑞生物科技有限公司 | 密蛋白18.2结合部分和其用途 |
| CN109762067B (zh) | 2019-01-17 | 2020-02-28 | 北京天广实生物技术股份有限公司 | 结合人Claudin 18.2的抗体及其用途 |
| CA3128502A1 (en) | 2019-02-01 | 2020-08-06 | Novarock Biotherapeutics, Ltd. | Anti-claudin 18 antibodies and methods of use thereof |
| MX2021011489A (es) | 2019-04-01 | 2021-10-22 | Jiangsu Hengrui Medicine Co | Anticuerpo anti-claudina 18.2 y utilizacion del mismo. |
| EP4069738A1 (en) * | 2019-12-06 | 2022-10-12 | SOTIO Biotech a.s. | Humanized cldn18.2 antibodies |
| CN114901365B (zh) * | 2019-12-23 | 2025-07-15 | 斯迪安生物技术公司 | 肿瘤特异性密蛋白18.2抗体 |
| CN113929780A (zh) | 2020-07-13 | 2022-01-14 | 北京凯因科技股份有限公司 | 一种结合密蛋白的用于治疗癌症的人源化抗体 |
-
2021
- 2021-12-23 CA CA3199830A patent/CA3199830A1/en active Pending
- 2021-12-23 KR KR1020237024767A patent/KR20230124037A/ko not_active Withdrawn
- 2021-12-23 JP JP2023538891A patent/JP2024500242A/ja active Pending
- 2021-12-23 EP EP21847946.7A patent/EP4267194A1/en not_active Withdrawn
- 2021-12-23 PE PE2023001921A patent/PE20231561A1/es unknown
- 2021-12-23 WO PCT/EP2021/087495 patent/WO2022136642A1/en not_active Ceased
- 2021-12-23 CN CN202180085938.6A patent/CN116635085A/zh active Pending
- 2021-12-23 MX MX2023007644A patent/MX2023007644A/es unknown
- 2021-12-23 AU AU2021405049A patent/AU2021405049A1/en not_active Abandoned
- 2021-12-23 US US18/269,240 patent/US20240100180A1/en active Pending
- 2021-12-23 IL IL302894A patent/IL302894A/en unknown
- 2021-12-23 TW TW110148442A patent/TW202241519A/zh unknown
-
2023
- 2023-05-11 ZA ZA2023/05221A patent/ZA202305221B/en unknown
- 2023-06-16 CL CL2023001800A patent/CL2023001800A1/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JPWO2022136642A5 (https=) | ||
| JP2022046569A5 (https=) | ||
| TWI851552B (zh) | 磷脂醯肌醇蛋白聚醣(glypican)3抗體及其結合物 | |
| EP2523972B1 (en) | Threevalent antibodies | |
| JP6454269B2 (ja) | Ｃｄ３３抗体及び癌を処置するためのその使用 | |
| JP7576779B2 (ja) | 抗体－ｓｔｉｎｇアゴニスト複合体および免疫療法におけるそれらの使用 | |
| RU2002125514A (ru) | SCFV против EGFRVIII с улучшенной цитотоксичностью и выходом, иммунотоксины на их основе, и способы их применения | |
| EP4087613A1 (en) | Anti-slc34a2 antibodies, antibody drug conjugates, and methods of use thereof | |
| JP2018520991A5 (https=) | ||
| CN110575547B (zh) | 靶向于tf的抗体-药物偶联物及其制法和用途 | |
| JP2026026483A (ja) | 標的化デンドリマー複合体 | |
| JP2003523771A5 (https=) | ||
| CN115197297A (zh) | 连接子、缀合物及其应用 | |
| JP2020506685A5 (https=) | ||
| JP2021525724A (ja) | プロドラッグおよび複合体に使用する修飾自己切断部分ならびにその使用方法および製造方法 | |
| JP2025183307A5 (https=) | ||
| US12539336B2 (en) | Antibody, linkers, payload, conjugates and applications thereof | |
| JP7675818B2 (ja) | 抗クローディン－１８．２抗体及びその抗体薬物複合体 | |
| JP2020532523A (ja) | 抗ｅｇｆｒ抗体薬物コンジュゲート（ａｄｃ）及びその使用 | |
| JP2018138538A (ja) | リンカー−薬物およびこれを用いた抗体−薬物複合体（ａｄｃ） | |
| JP2025509152A (ja) | 抗ＣａｎＡｇ抗体複合体 | |
| CN109790178B (zh) | 新颖细胞毒性剂和其缀合物 | |
| JP2025523117A (ja) | リンカー、コンジュゲート及びその用途 | |
| KR20190108351A (ko) | Folr1에 특이적으로 결합하는 항체 및 그의 용도 | |
| JP2020532543A (ja) | 抗ｅｇｆｒ抗体薬物コンジュゲート（ａｄｃ）及びその使用 |